CoChat
Sign Up
Cited by 440Parkinson's Disease Mechanisms and TreatmentsMitochondrial Function and PathologyAutophagy in Disease and Therapy

The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.

The Mitochondrial Fusion-Promoting Factor Mitofusin Is a Substrate of the PINK1/Parkin Pathway

Open access
Poole, Angela C., Thomas, Ruth E., Yu, Selina, Vincow, Evelyn S., Pallanck, Leo·2010·PLoS ONE
DOI 10.1371/journal.pone.0010054PMC PMC2850930
Open this paper in CoChat — free accountOpen PDF

Abstract

Loss-of-function mutations in the PINK1 or parkin genes result in recessive heritable forms of parkinsonism. Genetic studies of Drosophila orthologs of PINK1 and parkin indicate that PINK1, a mitochondrially targeted serine/threonine kinase, acts upstream of Parkin, a cytosolic ubiquitin-protein ligase, to promote mitochondrial fragmentation, although the molecular mechanisms by which the PINK1/Parkin pathway promotes mitochondrial fragmentation are unknown. We tested the hypothesis that PINK1 and Parkin promote mitochondrial fragmentation by targeting core components of the mitochondrial morphogenesis machinery for ubiquitination. We report that the steady-state abundance of the mitochondrial fusion-promoting factor Mitofusin (dMfn) is inversely correlated with the activity of PINK1 and Parkin in Drosophila. We further report that dMfn is ubiquitinated in a PINK1- and Parkin-dependent fashion and that dMfn co-immunoprecipitates with Parkin. By contrast, perturbations of PINK1 or Parkin did not influence the steady-state abundance of the mitochondrial fission-promoting factor Drp1 or the mitochondrial fusion-promoting factor Opa1, or the subcellular distribution of Drp1. Our findings suggest that dMfn is a direct substrate of the PINK1/Parkin pathway and that the mitochondrial morphological alterations and tissue degeneration phenotypes that derive from mutations in PINK1 and parkin result at least in part from reduced ubiquitin-mediated turnover of dMfn.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0010054

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Western blot analysis showing specificity of antisera that recognize Drosophila dMfn, Opa1, and Drp1. (A) Protein extracts from wt flies and flies expressing either the UAS-dmfn-RNAiVienna or UAS-dmfn-RNAiGuo transgenes targeting the dmfn gene were subjected to western blot analysis with an anti-dMfn antiserum. The hsp70-GAL4 driver was used to induce expression of the dmfn-RNAi transgenes, and flies were collected for analysis 24 to 48 hrs after a 3-hr heat shock protocol. The arrow indicates the location of the dMfn band at 94 kDa. The asterisks (*) indicate two nonspecific bands detected at 80 kDa and 110 kDa. (B) Protein extracts from wt flies, flies bearing the UAS-Opa1-FLAG transgene and the mesoderm-specific 24B-GAL4 driver, and flies bearing the UAS-opa1RNAi transgene and the muscle-specific dmef2-GAL4 driver were subjected to western blot analysis with an anti-Opa1 antiserum. (C) Protein extracts from wt flies, flies bearing the UAS-Drp1-HA transgene and the muscle-specific dmef2-GAL4 driver, and flies heterozygous for the Df(2L)Excel6008 deletion chromosome (which removes the drp1 gene) were subjected to western blot analysis with an affinity-purified anti-Drp1 antiserum.
Figure 1 Western blot analysis showing specificity of antisera that recognize Drosophila dMfn, Opa1, and Drp1. (A) Protein extracts from wt flies and flies expressing either the UAS-dmfn-RNAiVienna or UAS-dmfn-RNAiGuo transgenes targeting the dmfn gene were subjected to western blot analysis with an anti-dMfn antiserum. The hsp70-GAL4 driver was used to induce expression of the dmfn-RNAi transgenes, and flies were collected for analysis 24 to 48 hrs after a 3-hr heat shock protocol. The arrow indicates the location of the dMfn band at 94 kDa. The asterisks (*) indicate two nonspecific bands detected at 80 kDa and 110 kDa. (B) Protein extracts from wt flies, flies bearing the UAS-Opa1-FLAG transgene and the mesoderm-specific 24B-GAL4 driver, and flies bearing the UAS-opa1RNAi transgene and the muscle-specific dmef2-GAL4 driver were subjected to western blot analysis with an anti-Opa1 antiserum. (C) Protein extracts from wt flies, flies bearing the UAS-Drp1-HA transgene and the muscle-specific dmef2-GAL4 driver, and flies heterozygous for the Df(2L)Excel6008 deletion chromosome (which removes the drp1 gene) were subjected to western blot analysis with an affinity-purified anti-Drp1 antiserum.CC BY · PubMed Central
Figure 2 Perturbations of PINK1 and parkin specifically influence dMfn abundance. Protein extracts from wt males (m), PINK1B9 hemizygous males, wt males and females (m and f) and park25 males and females were subjected to western blot analysis with an affinity-purified anti-dMfn antiserum (A), an anti-Opa1 antiserum (C), an affinity-purified anti-Drp1 antiserum (D), an anti-complex V β antiserum (A, C, D), an anti-VDAC antiserum (A, C, D), and an anti-actin antiserum (A, C, D). Arrow in (A) indicates location of the dMfn band at 94 kDa and the asterisks (*) indicate nonspecific bands. (B) Quantification of dMfn abundance in PINKB9 and park25 null mutants relative to wt controls. Because PINK1B9 males are sterile and the PINK1 gene resides on the X chromosome, we are only able to generate male PINK1B9 mutants and thus used wt males as the control population for these mutants. The ratio of dMfn to actin abundance was obtained from three independent blots for each sample analyzed; the ratios for wt controls were set at a value of 1 and mutant ratios were normalized to the wt ratios. *p<0.05 by Student’s t-test. (E) Protein extracts from mitochondrial and cytosolic fractions (see Materials and Methods section for details on fractionation) were subjected to western blot analysis with an affinity-purified anti-Drp1 antiserum, an anti-complex V β (CompV) antiserum, an anti-VDAC antiserum, and an anti-actin antiserum. (F) Protein extracts from wt flies, flies overexpressing Parkin (hsp70-GAL4/UAS-Parkin) and flies overexpressing PINK1 (hsp70-GAL4/UAS-PINK1) were subjected to western blot analysis with an affinity-purified anti-dMfn antiserum, an anti-complex V β antiserum, an anti-VDAC antiserum, and an anti-actin antiserum. Flies were subjected to a 1-hr heat shock and collected for analysis 24 hrs following the heat shock. The arrow indicates the location of the dMfn band at 94 kDa and the asterisks (*) indicate the two nonspecific bands.
Figure 2 Perturbations of PINK1 and parkin specifically influence dMfn abundance. Protein extracts from wt males (m), PINK1B9 hemizygous males, wt males and females (m and f) and park25 males and females were subjected to western blot analysis with an affinity-purified anti-dMfn antiserum (A), an anti-Opa1 antiserum (C), an affinity-purified anti-Drp1 antiserum (D), an anti-complex V β antiserum (A, C, D), an anti-VDAC antiserum (A, C, D), and an anti-actin antiserum (A, C, D). Arrow in (A) indicates location of the dMfn band at 94 kDa and the asterisks (*) indicate nonspecific bands. (B) Quantification of dMfn abundance in PINKB9 and park25 null mutants relative to wt controls. Because PINK1B9 males are sterile and the PINK1 gene resides on the X chromosome, we are only able to generate male PINK1B9 mutants and thus used wt males as the control population for these mutants. The ratio of dMfn to actin abundance was obtained from three independent blots for each sample analyzed; the ratios for wt controls were set at a value of 1 and mutant ratios were normalized to the wt ratios. *p<0.05 by Student’s t-test. (E) Protein extracts from mitochondrial and cytosolic fractions (see Materials and Methods section for details on fractionation) were subjected to western blot analysis with an affinity-purified anti-Drp1 antiserum, an anti-complex V β (CompV) antiserum, an anti-VDAC antiserum, and an anti-actin antiserum. (F) Protein extracts from wt flies, flies overexpressing Parkin (hsp70-GAL4/UAS-Parkin) and flies overexpressing PINK1 (hsp70-GAL4/UAS-PINK1) were subjected to western blot analysis with an affinity-purified anti-dMfn antiserum, an anti-complex V β antiserum, an anti-VDAC antiserum, and an anti-actin antiserum. Flies were subjected to a 1-hr heat shock and collected for analysis 24 hrs following the heat shock. The arrow indicates the location of the dMfn band at 94 kDa and the asterisks (*) indicate the two nonspecific bands.CC BY · PubMed Central
Figure 3 dMfn is ubiquitinated in a PINK1- and Parkin-dependent fashion. Affinity purified anti-dMfn antiserum was used to immunoprecipitate dMfn from wild-type flies, PINK1B9 mutants, and park25 mutants. As a control for specificity, anti-dMfn antiserum was also used to immunoprecipitate dMfn from flies with hsp70-GAL4 driven expression of UAS-dmfn-RNAiVienna. In the left panel, 3% of the lysate input used in the immunoprecipitations was subjected to western blot analysis using an anti-ubiquitin antiserum to show that general ubiquitination levels were similar in all genotypes. In the middle and right panels, dMfn immunoprecipitates from all four genotypes were subjected to western blot analysis with either anti-ubiquitin antiserum (middle panel) or anti-dMfn antiserum (right panel). Arrow indicates the unmodified dMfn species detected in wt flies, PINK1B9 mutants, and park25 mutants, with reduced levels in flies expressing UAS-dmfn-RNAiVienna. Arrowhead indicates location of ubiquitinated dMfn species. These analyses were replicated at least three times with similar results.
Figure 3 dMfn is ubiquitinated in a PINK1- and Parkin-dependent fashion. Affinity purified anti-dMfn antiserum was used to immunoprecipitate dMfn from wild-type flies, PINK1B9 mutants, and park25 mutants. As a control for specificity, anti-dMfn antiserum was also used to immunoprecipitate dMfn from flies with hsp70-GAL4 driven expression of UAS-dmfn-RNAiVienna. In the left panel, 3% of the lysate input used in the immunoprecipitations was subjected to western blot analysis using an anti-ubiquitin antiserum to show that general ubiquitination levels were similar in all genotypes. In the middle and right panels, dMfn immunoprecipitates from all four genotypes were subjected to western blot analysis with either anti-ubiquitin antiserum (middle panel) or anti-dMfn antiserum (right panel). Arrow indicates the unmodified dMfn species detected in wt flies, PINK1B9 mutants, and park25 mutants, with reduced levels in flies expressing UAS-dmfn-RNAiVienna. Arrowhead indicates location of ubiquitinated dMfn species. These analyses were replicated at least three times with similar results.CC BY · PubMed Central
Figure 4 dMfn assembles with Parkin. Affinity purified anti-Parkin antiserum was used to immunoprecipitate Parkin from wt flies and park25 null mutants. As park25 flies do not produce any Parkin protein, this immunoprecipitation serves as a control for any nonspecific binding of other proteins to the anti-Parkin antiserum. Three percent of the total amount of lysate used for the immunoprecipitations as well as the Parkin immunoprecipitates were subjected to western blot analysis with the anti-dMfn antiserum. Only in the wt flies did a band corresponding to the dMfn band appear indicating an interaction between Parkin and dMfn. The asterisks (*) indicate the nonspecific bands.
Figure 4 dMfn assembles with Parkin. Affinity purified anti-Parkin antiserum was used to immunoprecipitate Parkin from wt flies and park25 null mutants. As park25 flies do not produce any Parkin protein, this immunoprecipitation serves as a control for any nonspecific binding of other proteins to the anti-Parkin antiserum. Three percent of the total amount of lysate used for the immunoprecipitations as well as the Parkin immunoprecipitates were subjected to western blot analysis with the anti-dMfn antiserum. Only in the wt flies did a band corresponding to the dMfn band appear indicating an interaction between Parkin and dMfn. The asterisks (*) indicate the nonspecific bands.CC BY · PubMed Central
Figure 5 A potential model by which the PINK1/Parkin pathway promotes mitochondrial fragmentation and turnover. Previous work has shown that PINK1 localizes to the outer mitochondrial membrane with its kinase domain facing the cytoplasm [28], [39], where it is required to recruit Parkin selectively to damaged mitochondria to promote the autophagic clearance of these mitochondria [27], [28], [29], [30], [31]. Our model postulates that upon Parkin recruitment to damaged portions of the mitochondrial reticulum, it ubiquitinates (Ub) the mitochondrial fusion-promoting factor Mitofusin, thus tagging it for degradation, or otherwise inactivating its fusion-promoting activity. Subsequent Drp1-dependent mitochondrial fission would yield a damaged mitochondrial product that is deficient in Mitofusin, and thus unable to re-enter the mitochondrial network. These small damaged mitochondrial fission products would instead be targeted for autophagic degradation. Although our figure depicts a model in which Parkin binds prior to mitochondrial fission, Parkin could also be recruited to damaged mitochondria following fission. An alternative model is that the ubiquitination of Mitofusin serves as a signal for the turnover of damaged mitochondria. These possible models are not mutually exclusive.
Figure 5 A potential model by which the PINK1/Parkin pathway promotes mitochondrial fragmentation and turnover. Previous work has shown that PINK1 localizes to the outer mitochondrial membrane with its kinase domain facing the cytoplasm [28], [39], where it is required to recruit Parkin selectively to damaged mitochondria to promote the autophagic clearance of these mitochondria [27], [28], [29], [30], [31]. Our model postulates that upon Parkin recruitment to damaged portions of the mitochondrial reticulum, it ubiquitinates (Ub) the mitochondrial fusion-promoting factor Mitofusin, thus tagging it for degradation, or otherwise inactivating its fusion-promoting activity. Subsequent Drp1-dependent mitochondrial fission would yield a damaged mitochondrial product that is deficient in Mitofusin, and thus unable to re-enter the mitochondrial network. These small damaged mitochondrial fission products would instead be targeted for autophagic degradation. Although our figure depicts a model in which Parkin binds prior to mitochondrial fission, Parkin could also be recruited to damaged mitochondria following fission. An alternative model is that the ubiquitination of Mitofusin serves as a signal for the turnover of damaged mitochondria. These possible models are not mutually exclusive.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

Sorted by citations

Items 301–400 of 440

Related

See all

Metadata

Authors
Poole, A. C., Thomas, R. E., Yu, S., Vincow, E. S., & Pallanck, L.
Affiliations
University of Washington (US)
Corresponding author
Pallanck, Leo
ORCID
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2010-04-07
Volume
5
Issue
4
Pages
e10054
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0010054
PMC
PMC2850930
OpenAlex
W2054556550
Cited by
440
References
41
Citations by year
2026: 4 · 2025: 4 · 2024: 17 · 2023: 14 · 2022: 13 · 2021: 26 · 2020: 35 · 2019: 16 · 2018: 26 · 2017: 27 · 2016: 30 · 2015: 39 · 2014: 38 · 2013: 44 · 2012: 54
FWCI
28.77
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Institutes of Health
  • National Institute on Aging (T32AG000057)
  • National Institute of General Medical Sciences (R01GM086394)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
Keywords
mitofusins, PINK1, Parkin, PINK1/Parkin pathway, mitochondrial fusion, mitochondrial fragmentation, ubiquitination, parkinsonism, Drp1, OPA1, Drosophila, mitochondrial morphogenesis
MeSH terms
PTEN-Induced Putative Kinase, Membrane Proteins, Mitochondria, Mutation, Protein Serine-Threonine Kinases, Drosophila Proteins, Ubiquitin-Protein Ligases, Immunoprecipitation, Ubiquitination, Protein Stability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review